TFA Therapeutics, Inc. (RAJAF)
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- Last price
- $9.18
- As of
Kresmion compiles this page from RAJAF's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
TFA Therapeutics, Inc. (RAJAF): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-09-02.
See the full RAJAF dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for RAJAF on one page. Preview it with sample data, then open it live with a free account.
Preview the RAJAF dossierActive events for RAJAF
No recent events on RAJAF in the last 180 days.
FREE, NO ACCOUNT
Every event on RAJAF, as it fires
New filings, 13F moves and cross asset events on RAJAF land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter.
Recent SEC filings, RAJAF
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 20-FSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 20-FSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 20-FSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
Going concern statement
RAJAF's 20-F filed May 15, 2026 states:
The following factors among others raise substantial doubt about the Company's ability to continue as a going concern for a reasonable period of time.
Read the 20-F on SEC EDGAR Every company with a going concern statement
More data on RAJAF
RAJAF against its peers
RAJAF's operating margin of -11.3% ranks in the 14th percentile of 10 Packaged Foods sub-industry peers, fiscal periods ending between 2025-03-31 and 2026-01-31.
| Metric | RAJAF | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 1.2M USD | 671M USD | 14 | 10 |
| Revenue YoY | -0.6% | n/a | n/a | 2 |
| Gross margin | 61.1% | 25.1% | 88 | 11 |
| Operating margin | -11.3% | 2.7% | 14 | 10 |
| Net margin | -12.4% | 0.1% | 21 | 11 |
| Return on equity | n/a | 4.6% | n/a | 9 |
Peers (13): WEST, SENEB, MAMA, UTZ, OTLY, BRCC, BFNH, NATR, BGS, WYHG, ENHA, UMEW, MICC. Left out: MALG (period gap), ARZTF (no annual filing), CZZLF (no annual filing), TUFBY (no annual filing), OFRM (no annual filing), NCHEF (no annual filing), PRE (period gap), PIFMF (no annual filing), NHFOF (no annual filing), UCFI (no annual filing), MBRFY (no annual filing), GBCMY (no annual filing). Fiscal periods ending between 2025-03-31 and 2026-01-31. Every figure is one full fiscal year read from one annual filing (RAJAF: 20-F), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in RAJAF on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on RAJAF in the last 180 days.
Upstream: SEC EDGAR filings for RAJAF
Kresmion, "TFA Therapeutics, Inc. (RAJAF) institutional holdings and SEC filings", data as of 2026-09-02, https://kresmion.com/research/RAJAF. Upstream data: SEC EDGAR filings for RAJAF.
Link to this data (HTML):
<a href="https://kresmion.com/research/RAJAF">TFA Therapeutics, Inc. (RAJAF) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow RAJAF on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to RAJAF for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.